Month: August 2025

Successful completion of strategic reorganization, reducing debt by $1.15 billion.In connection with emergence on 6/24/25, fiscal Q2 consists of a “Predecessor” period from 3/30/25 to 6/24/25, and a “Successor” period from 6/25/25 to 6/30/25 Combined End of Period Subscribers1 of 3.2 million; Combined End of Period Clinical Subscribers1 of 127 thousand Combined Revenues1 of $189 million, down 6% vs. prior year; Combined Clinical Revenues1 of $31 million, up 55% vs. prior year Predecessor Net Income1 of $1,191 million and Net Margin1 of 673% were impacted by Reorganization items; Successor Net Income1 of $1 million and Net Margin1 of 10%; Predecessor Adjusted EBITDA1,2 of $61 million and Adjusted Margin1,2 of 34%; Successor Adjusted EBITDA1,2 of $4 million and Adjusted Margin1,2 of 37% NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE)...

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early 2026 Company entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, with up to $750 million in potential total payments Well-capitalized with $1 billion in cash as of July 31, 2025, and runway into the second half of 2028 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN,...

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a significant improvement versus standard of care which is dosed every two weeks, is ongoing with 52-week readout anticipated in 1H 2026 Driven by strong enrollment, APEX Phase 2 Part B of APG777 readout accelerated to mid-2026 First patient dosed in Phase 1b head-to-head trial of APG279 (IL-13 + OX40L) vs. DUPIXENT in atopic dermatitis, with readout expected in 2H 2026 $621.2 million cash, cash equivalents and marketable securities supports runway into Q1 2028 SAN FRANCISCO and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage...

Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025 All other clinical trials in previously announced six-indications remain on track with increased focus on clinical execution Remission data from the batoclimab proof-of-concept study in GD to be reported at the American Thyroid Association (ATA) Annual Meeting in September 2025 Current cash balance provides runway for announced indications through GD readout expected in 2027NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025. Recent...